… Improving the specificity of disease recognition and treatment in a rational way is neither
hope nor hype. It is simply good medicine. The cost of sequencing a human genome has …

In the recently published Heart Outcomes Prevention Evaluation (HOPE study), 1 treatment
with the ACE inhibitor ramipril was reported to reduce cardiovascular morbidity and mortality …

… Patients in clinical trials are younger with a mean age of 63 years, and are predominately
men (81%), with ischemic heart disease as the primary cause in two thirds of the cases (Table 2…

… The patients were deemed to be at high risk for cardiovascular disease by virtue of a prior
history of coronary heart disease, stroke, peripheral vascular disease or diabetes, plus at least …

Purpose of the review Machine learning (ML) approaches have emerged as powerful tools
in medicine. This review focuses on the use ML to assess risk of events in patients with heart …

The 2019 annual meeting of the American Heart Association, which was held in Philadelphia,
was marked by considerable buzz around a presentation on the International Study of …

… heart disease, primary cardiomyopathies, viral cardiomyopathies and valvular disease. …
preceding and causing heart failure (possibly causative in ischemic heart disease, likely …

… STAGE A At high risk for HF but without structural heart disease or symptoms of HF. … This
study provided hope that perhaps this slow regenerative capacity of the heart can be exploited …

… Conversely, promising fields of application of PET/MR imaging include suspected coronary
artery disease, myocardial viability and heart failure, and inflammatory heart diseases such …

Information can be an important tool in promoting a prevention strategy to address the
emerging epidemic of cardiovascular disease in developing countries. Advances in information …